BLB&B Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $302K | Sell |
5,756
-93
| -2% | -$4.92K | 0.01% | 241 |
|
|
2026
Q1 | $323K | Buy |
5,849
+69
| +1% | +$3.74K | 0.01% | 225 |
|
|
2025
Q4 | $283K | Sell |
5,780
-207
| -3% | -$9.65K | 0.01% | 241 |
|
|
2025
Q3 | $258K | Hold |
5,987
| – | – | 0.01% | 245 |
|
|
2025
Q2 | $230K | Buy |
5,987
+173
| +3% | +$6.61K | 0.01% | 251 |
|
|
2025
Q1 | $225K | Buy |
+5,814
| New | +$213K | 0.01% | 256 |
|
|
2024
Q4 | – | Sell |
-6,131
| Closed | -$251K | – | 279 |
|
|
2024
Q3 | $251K | Hold |
6,131
| – | – | 0.01% | 246 |
|
|
2024
Q2 | $236K | Hold |
6,131
| – | – | 0.01% | 246 |
|
|
2024
Q1 | $263K | Sell |
6,131
-240
| -4% | -$9.9K | 0.01% | 239 |
|
|
2023
Q4 | $236K | Sell |
6,371
-105
| -2% | -$3.77K | 0.01% | 237 |
|
|
2023
Q3 | $235K | Sell |
6,476
-196
| -3% | -$6.96K | 0.02% | 223 |
|
|
2023
Q2 | $238K | Sell |
6,672
-476
| -7% | -$17.1K | 0.02% | 226 |
|
|
2023
Q1 | $254K | Sell |
7,148
-9,221
| -56% | -$323K | 0.02% | 213 |
|
|
2022
Q4 | $575K | Buy |
16,369
+8,226
| +101% | +$274K | 0.04% | 143 |
|
|
2022
Q3 | $240K | Sell |
8,143
-241
| -3% | -$9.13K | 0.02% | 213 |
|
|
2022
Q2 | $456K | Sell |
8,384
-668
| -7% | -$36.9K | 0.04% | 161 |
|
|
2022
Q1 | $493K | Sell |
9,052
-794
| -8% | -$43.1K | 0.03% | 164 |
|
|
2021
Q4 | $543K | Sell |
9,846
-2,403
| -20% | -$125K | 0.04% | 160 |
|
|
2021
Q3 | $585K | Buy |
12,249
+1,136
| +10% | +$57.1K | 0.04% | 165 |
|
|
2021
Q2 | $553K | Sell |
11,113
-3,545
| -24% | -$170K | 0.04% | 163 |
|
|
2021
Q1 | $654K | Sell |
14,658
-9,566
| -39% | -$434K | 0.05% | 150 |
|
|
2020
Q4 | $1.11M | Sell |
24,224
-1,041
| -4% | -$47.8K | 0.09% | 117 |
|
|
2020
Q3 | $1.19M | Sell |
25,265
-2,265
| -8% | -$113K | 0.12% | 101 |
|
|
2020
Q2 | $1.4M | Sell |
27,530
-2,568
| -9% | -$132K | 0.15% | 95 |
|
|
2020
Q1 | $1.43M | Sell |
30,098
-376
| -1% | -$20.1K | 0.19% | 89 |
|
|
2019
Q4 | $1.79M | Sell |
30,474
-592
| -2% | -$32.9K | 0.19% | 97 |
|
|
2019
Q3 | $1.66M | Sell |
31,066
-898
| -3% | -$46.2K | 0.19% | 99 |
|
|
2019
Q2 | $1.6M | Sell |
31,964
-2,316
| -7% | -$116K | 0.18% | 107 |
|
|
2019
Q1 | $1.79M | Sell |
34,280
-3,789
| -10% | -$189K | 0.21% | 102 |
|
|
2018
Q4 | $1.82M | Sell |
38,069
-2,467
| -6% | -$121K | 0.25% | 92 |
|
|
2018
Q3 | $2.04M | Sell |
40,536
-1,506
| -4% | -$76.5K | 0.25% | 96 |
|
|
2018
Q2 | $2.12M | Sell |
42,042
-1,008
| -2% | -$50.8K | 0.29% | 89 |
|
|
2018
Q1 | $2.1M | Buy |
43,050
+182
| +0.4% | +$8.48K | 0.28% | 92 |
|
|
2017
Q4 | $1.9M | Sell |
42,868
-7,553
| -15% | -$349K | 0.27% | 94 |
|
|
2017
Q3 | $2.56M | Sell |
50,421
-7,268
| -13% | -$369K | 0.39% | 75 |
|
|
2017
Q2 | $3.11M | Buy |
57,689
+1,731
| +3% | +$92.3K | 0.52% | 60 |
|
|
2017
Q1 | $2.95M | Buy |
55,958
+3,904
| +7% | +$198K | 0.5% | 60 |
|
|
2016
Q4 | $2.51M | Buy |
52,054
+1,369
| +3% | +$67.6K | 0.44% | 72 |
|
|
2016
Q3 | $2.73M | Buy |
50,685
+1,368
| +3% | +$75K | 0.5% | 62 |
|
|
2016
Q2 | $2.67M | Buy |
49,317
+2,451
| +5% | +$129K | 0.5% | 58 |
|
|
2016
Q1 | $2.38M | Buy |
46,866
+2,284
| +5% | +$114K | 0.48% | 68 |
|
|
2015
Q4 | $2.25M | Buy |
44,582
+3,778
| +9% | +$193K | 0.48% | 70 |
|
|
2015
Q3 | $1.96M | Buy |
40,804
+998
| +3% | +$52K | 0.43% | 75 |
|
|
2015
Q2 | $2.07M | Buy |
39,806
+11,147
| +39% | +$628K | 0.43% | 70 |
|
|
2015
Q1 | $1.65M | Buy |
28,659
+13,277
| +86% | +$761K | 0.34% | 83 |
|
|
2014
Q4 | $822K | Buy |
15,382
+3,269
| +27% | +$183K | 0.17% | 113 |
|
|
2014
Q3 | $696K | Buy |
12,113
+27
| +0.2% | +$1.66K | 0.15% | 129 |
|
|
2014
Q2 | $808K | Buy |
12,086
+80
| +0.7% | +$5.42K | 0.17% | 119 |
|
|
2014
Q1 | $802K | Buy |
12,006
+80
| +0.7% | +$5.41K | 0.18% | 125 |
|
|
2013
Q4 | $796K | Sell |
11,926
-164
| -1% | -$10.6K | 0.19% | 110 |
|
|
2013
Q3 | $758K | Sell |
12,090
-40
| -0.3% | -$2.58K | 0.2% | 110 |
|
|
2013
Q2 | $758K | Buy |
+12,130
| New | +$770K | 0.21% | 107 |
|
Other funds holding GSK
JEST
BLB&B Advisors's GSK Position: Q2 2026 in Review
BLB&B Advisors reduced its GSK (GSK) stake by 1.6% in Q2 2026, selling an estimated $4.92K and leaving 5,756 shares worth $302K. The position accounts for 0.01% of the portfolio, ranked #241.
BLB&B Advisors first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.11M in Q2 2017. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- BLB&B Advisors held 5,756 shares of GSK worth $302K as of Q2 2026.
- BLB&B Advisors sold 93 GSK shares in Q2 2026, an estimated $4.92K.
- GSK made up 0.01% of BLB&B Advisors's portfolio in Q2 2026, its #241 holding.
- BLB&B Advisors first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
- BLB&B Advisors's GSK position peaked at $3.11M in Q2 2017.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on BLB&B Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.